NEUREN PHARMACEUTICALS LIMITED (NEU)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

NEU

NEU - NEUREN PHARMACEUTICALS LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: December
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 0
Index: ASX200 | ASX300 | ALL-ORDS

Neuren Pharmaceuticals develops treatments for serious neurological and neurodevelopmental disorders.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$23.24

05 Nov
2026

3.460

OPEN

$20.99

17.49%

HIGH

$23.30

1,096,995

LOW

$20.98

TARGET
$26.767

+0.90 change from previous day

 15.2% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGN . ARX . ATH . AVH . BIO . BOT . COV . CSL . CUV . DXB . GSS . IDT . ILA . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NUZ . OCC . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
NEU: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx 23.7 42.5 xxx
DPS (cps) xxx 0.0 33.0 xxx
EPS Growth xxx - 78.7% 79.2% xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 54.6 xxx
Dividend Yield xxx N/A 1.4% xxx
Div Pay Ratio(%) xxx N/A 77.6% xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 15/09 - ex-div 15.00c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx23.7
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx64.6 M
Book Value Per Share xxxxxxxxxxxxxxx267.3
Net Operating Cash Flow xxxxxxxxxxxxxxx125.4 M
Net Profit Margin xxxxxxxxxxxxxxx47.09 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx8.67 %
Return on Invested Capital xxxxxxxxxxxxxxx8.67 %
Return on Assets xxxxxxxxxxxxxxx8.09 %
Return on Equity xxxxxxxxxxxxxxx8.67 %
Return on Total Capital xxxxxxxxxxxxxxx6.27 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx125.4 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx0 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx296 M
Price To Book Value xxxxxxxxxxxxxxx6.96

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx0.0 M
Capex % of Sales xxxxxxxxxxxxxxx0.06 %
Cost of Goods Sold xxxxxxxxxxxxxxx0 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx43 M
Research & Development xxxxxxxxxxxxxxx36 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

3
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

06/11/2026

1

Buy

$27.80

19.62%

Neuren Pharmaceuticals' licensing partner Acadia announced strong 3Q26 Daybue sales, up 12% q/q, and 7% ahead of consensus, with estimated royalties to Neuren of US$16m, Ord Minnett explains.

The new STIX formulation accounted for over 50% of sales, supporting new patient uptake and treatment resumption.

Acadia upgraded FY26 Daybue sales guidance to US$505m-US$520m from US$480m-US$510m and reaffirmed its US$700m target for 2028.

The analyst highlights stronger royalty and milestone revenues supporting Neuren's cash position and dividend capacity, while Daybue's success provides confidence in NNZ-2591, with Phase III results expected in late 2027.

FY26 and FY27 EPS forecasts are increased by 5.3% and 6.9%. Buy retained. Target increased to $27.80 from $27.60.

FORECAST
Ord Minnett forecasts a full year FY26 EPS of 42.00 cents.
Ord Minnett forecasts a full year FY27 EPS of 55.00 cents.

Bell Potter

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

01/09/2026

1

Buy

$24.76

6.54%

Canaccord Genuity maintains a Buy rating for Neuren Pharmaceuticals with a $24.76 target price following the release of 1H26 results featuring a $33.2m royalty stream and a maiden dividend declaration.

The company declared an initial 15c per share dividend based on a target payout ratio of 70% to 100%, and finished the half with $287m in cash.

Reported EBIT of $7.6m and NPAT of $4.9m fell below forecasts due to higher research and development expenses associated with advancing the NNZ-2591 pipeline.

Near-term milestones include a planned Daybue commercial launch in Germany triggering a US$35m payment and upcoming top-line results from a Japanese trial.

The analyst views the established royalty franchise as a predictable funding source for second-drug development, noting clearer visibility on the NNZ-2591 clinical pathway is expected to unlock remaining valuation upside.
Access Extra Coverage Research History >

NEU STOCK CHART

FNArena News on NEU

1
Rudi’s View: Resources, Healthcare & Best Buys

Sep 03 2026 - Rudi's View
2
Australian Broker Call *Extra* Edition – Sep 01, 2026

Sep 01 2026 - Daily Market Reports
3
FNArena Corporate Results Monitor – 27-08-2026

Aug 27 2026 - Australia
4
Australian Broker Call *Extra* Edition – Aug 10, 2026

Aug 10 2026 - Daily Market Reports
5
Rudi’s View: Small Cap Favourites, AI & More

Jul 16 2026 - Rudi's View

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Telix Aims For A Strategic Isotope Supply Chain

Sep 24 2026 - Australia
2
CSL’s FY26 Suggests The Downtrend Is Done

Aug 19 2026 - Australia
3
Strong Result, Can Telix Continue To Deliver?

Jul 22 2026 - Australia
4
CSL Challenges Pile On, Where’s The Upside?

May 13 2026 - Australia
5
The Biotech ‘Industrialisation’

Apr 20 2026 - Small Caps
6
Telix’ Double-Product Strategy On A Roll

Apr 10 2026 - Australia
7
Focus On Telix’ Guidance Post Annus Horribilis

Jan 22 2026 - Australia
8
Anti-Vaxxers & China Cloud CSL’s Future

Oct 31 2025 - Australia
9
Rudi Interviewed: Diary Of A Successful Investor

Oct 20 2025 - Rudi's View
10
Is CSL Starting Its Price Recovery?

Sep 30 2025 - Technicals